Dr Agarwal's Health Care Q4 FY26 profit up 17.4%

Key takeaway from the March 2026 quarter

Dr Agarwal's Health Care reported a year-on-year rise in consolidated net profit for the quarter ended March 31, 2026, supported by strong growth in revenue and operating profit. The eye care service chain said Q4 net profit increased 17.4% to INR 50 crore, compared with INR 43 crore in the year-ago quarter. The update comes as the company also highlighted that FY26 marked the first time it crossed INR 2,000 crore in revenue from operations. The March quarter is described by the company as seasonally one of its best quarters. Alongside financial growth, Dr Agarwal's expanded its network with fresh facility additions during the quarter.

Q4 FY26: Profit, revenue, and margins

For Q4 FY26, the company reported revenue from operations of around INR 564 crore, with multiple references placing the figure at INR 564-565 crore and indicating about 22.6% year-on-year growth versus roughly INR 460 crore in Q4 FY25. Total income for the quarter was reported at INR 577 crore, up 21.2% year-on-year. Operating performance also improved, with Q4 EBITDA reported at INR 174 crore, reflecting 18.9% growth year-on-year. EBITDA margin for Q4 was stated at 30.2%, described as the highest quarterly margin for the year. Q4 profit after tax (PAT) was stated at INR 50 crore, with a Q4 PAT margin cited at 8.7%.

FY26: Revenue crosses INR 2,000 crore milestone

For the full year ended March 31, 2026, Dr Agarwal's said it crossed INR 2,000 crore in revenue from operations for the first time. Total income for FY26 was reported at INR 2,125 crore, up 20.9% year-on-year. Revenue from operations rose 21.6% to INR 2,080 crore. The company also reported a sharp increase in FY26 PAT, up 52.4% year-on-year to INR 168 crore, compared with INR 110 crore in FY25. A PAT margin figure of 7.9% for the year was cited in the update.

EBITDA growth and operating leverage

Dr Agarwal's reported FY26 EBITDA of INR 614 crore, up 22.2% year-on-year, with EBITDA margin at 28.9%. The company said margins improved by 31 basis points to 28.9% for the year. In Q4, EBITDA at INR 174 crore and margin at 30.2% were presented as evidence of operating leverage and seasonal strength. The company also noted that Q4 performance was delivered despite new facility openings during the quarter. These updates indicate that cost absorption improved as the network scaled, even while expansion continued.

Expansion in Q4: 19 new facilities added

A key operational datapoint for the March quarter was network expansion. The company said it opened 19 new facilities during Q4. This included 7 secondary facilities and 12 primary facilities. The company positioned the quarter as a period of disciplined execution across its network. While the statement did not provide a city-wise breakdown in the provided text, the facility additions were flagged as material in the context of quarterly performance.

India revenue details cited for Q4

The company also provided an India-specific number for Q4 revenue from operations. Revenue from operations in India for Q4 was stated at INR 505 crore, representing 22.2% year-on-year growth. This India figure sits within the consolidated Q4 revenue from operations of about INR 564-565 crore. The disclosure suggests that the India business contributed the bulk of quarterly operating revenue, with the balance coming from other geographies or segments.

Multiple net profit figures in circulation

The provided text includes another separate report stating Q4 net profit rose 22.15% year-on-year to INR 39.7 crore (from INR 32.5 crore), alongside Q4 revenue of INR 564 crore. In contrast, the company statement carried by PTI and repeated elsewhere in the text states consolidated Q4 net profit at INR 50 crore, up 17.4% year-on-year from INR 43 crore. Both figures appear in the provided material, and readers should rely on the company’s latest official filing or statement for the definitive quarter number.

Stock price movement mentioned alongside results

A stock price move was cited in the provided text after the results-related information. Dr Agarwals Health Care Ltd. share price was reported to have moved up 5.26% from its previous close of INR 510.80, with the stock last traded at INR 537.65. No additional intraday range, volume, or date context was included in the provided excerpt beyond these numbers.

Key reported numbers (Q4 FY26 and FY26)

Why these results matter for investors tracking healthcare services

The company’s update points to a combination of revenue growth and margin resilience during a quarter typically strong for the business. Crossing INR 2,000 crore in annual revenue from operations is a milestone that can influence how investors benchmark scale within listed healthcare services. The disclosed EBITDA margins, particularly the 30.2% in Q4, are important because they show the operating model’s ability to maintain profitability during expansion. At the same time, the presence of differing Q4 profit figures in the provided text underscores the need to verify the final quarter number through the company’s official results documents.

Conclusion

Dr Agarwal's Health Care reported higher consolidated profit and revenue for Q4 FY26 and a sharp increase in FY26 PAT, while expanding its network with 19 new facilities in the March quarter. The company also highlighted that FY26 revenue from operations crossed INR 2,000 crore for the first time. Investors will track how the company sustains margins alongside expansion, and will look to official disclosures for reconciliation of quarter-level profit figures cited across reports.